Literature DB >> 21182181

Monitoring of intracellular nitric oxide in leishmaniasis: its applicability in patients with visceral leishmaniasis.

Avijit Sarkar1, Piu Saha, Goutam Mandal, Debanjan Mukhopadhyay, Susmita Roy, Sunny Kumar Singh, Sukhen Das, R P Goswami, Bibhuti Saha, Deepak Kumar, Padma Das, Mitali Chatterjee.   

Abstract

Nitric oxide (NO) has been demonstrated to be a principal effector molecule responsible for mediating intracellular killing of Leishmania parasites, the causative organism of leishmaniasis. As measurement of intracellular NO remains a challenge to biologists, we have developed a flow cytometric approach to perform real time biological detection of NO within Leishmania parasites and parasitized macrophages using a membrane permeable derivative of diaminofluorescein [4,5-diaminofluorescein diacetate (DAF-2DA)]. Initially, assay optimization was performed in Leishmania donovani promastigotes, assay specificity being confirmed using both a NO donor [S-nitroso-N-acetyl-penicillamine (SNAP)] and a NO scavenger [2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide, C-PTIO]. Using 40 μM DAF-2DA, basal levels of intracellular NO were measured which varied in different Leishmania species; addition of conventional anti-leishmanial drugs, antimony and miltefosine translated into a dramatic increase in DAF-2T fluorescence. Furthermore, the assay also measured levels of NO in macrophages, but needed a 20 fold lower concentration of DAF-2DA, being 2 μM. Following parasitization, levels of NO decreased which was normalized following treatment with anti-leishmanial drugs. Similarly monocytes of patients with visceral leishmaniasis at disease presentation showed decreased levels of NO which too reverted on completion of treatment. Taken together, this study opens new perspectives of research regarding monocyte function and provides a real time approach for monitoring the effect of anti-leishmanial compounds.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21182181     DOI: 10.1002/cyto.a.21001

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  22 in total

1.  Impact of primary mouse macrophage cell types on Leishmania infection and in vitro drug susceptibility.

Authors:  M Van den Kerkhof; L Van Bockstal; J F Gielis; P Delputte; P Cos; L Maes; Guy Caljon; Sarah Hendrickx
Journal:  Parasitol Res       Date:  2018-08-23       Impact factor: 2.289

Review 2.  Leishmaniasis and Trace Element Alterations: a Systematic Review.

Authors:  Ali Taghipour; Amir Abdoli; Afifeh Ramezani; Ahmad Abolghazi; Mirza Ali Mofazzal Jahromi; Salar Maani; Seyede Manizhe Heidar Nejadi; Sima Rasti; Morteza Shams; Ezatollah Ghasemi
Journal:  Biol Trace Elem Res       Date:  2021-01-06       Impact factor: 3.738

3.  Inter- and intra-subject variability of nitric oxide levels in leukocyte subpopulations.

Authors:  Sheena Maharaj; Kim D Lu; Shlomit Radom-Aizik; Frank Zaldivar; Fadia Haddad; Hye-Won Shin; Szu-Yun Leu; Eliezer Nussbaum; Inderpal Randhawa; Dan M Cooper
Journal:  Nitric Oxide       Date:  2017-11-09       Impact factor: 4.427

4.  Collective nitric oxide production provides tissue-wide immunity during Leishmania infection.

Authors:  Romain Olekhnovitch; Bernhard Ryffel; Andreas J Müller; Philippe Bousso
Journal:  J Clin Invest       Date:  2014-03-10       Impact factor: 14.808

Review 5.  Leishmania antimony resistance: what we know what we can learn from the field.

Authors:  Khatima Aït-Oudhia; Elodie Gazanion; Baptiste Vergnes; Bruno Oury; Denis Sereno
Journal:  Parasitol Res       Date:  2011-07-29       Impact factor: 2.289

6.  A Defective Oxidative Burst and Impaired Antigen Presentation are Hallmarks of Human Visceral Leishmaniasis.

Authors:  Susmita Roy; Debanjan Mukhopadhyay; Shibabrata Mukherjee; Susmita Ghosh; Shishir Kumar; Kumkum Sarkar; Dipankar Pal; Pratik Bhowmik; Kausik Mandal; Dolanchampa Modak; Subhasish Kamal Guha; Netai Pramanik; Rama Prosad Goswami; Bibhuti Saha; Mitali Chatterjee
Journal:  J Clin Immunol       Date:  2014-11-25       Impact factor: 8.317

7.  Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis.

Authors:  Anthony D Duong; Sadhana Sharma; Kevin J Peine; Gaurav Gupta; Abhay R Satoskar; Eric M Bachelder; Barbra E Wyslouzil; Kristy M Ainslie
Journal:  Mol Pharm       Date:  2013-02-12       Impact factor: 4.939

8.  Antimony resistance and environment: Elusive links to explore during Leishmania life cycle.

Authors:  Denis Sereno; Carla Maia; Khatima Aït-Oudhia
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-09-03       Impact factor: 4.077

9.  UCP2 deficiency helps to restrict the pathogenesis of experimental cutaneous and visceral leishmaniosis in mice.

Authors:  Javier Carrión; M Angeles Abengozar; María Fernández-Reyes; Carlos Sánchez-Martín; Eduardo Rial; Gustavo Domínguez-Bernal; M Mar González-Barroso
Journal:  PLoS Negl Trop Dis       Date:  2013-02-21

10.  Berberine chloride mediates its anti-leishmanial activity via differential regulation of the mitogen activated protein kinase pathway in macrophages.

Authors:  Piu Saha; Surajit Bhattacharjee; Avijit Sarkar; Alak Manna; Subrata Majumder; Mitali Chatterjee
Journal:  PLoS One       Date:  2011-04-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.